By M. Marin
NASDAQ: QNRX
READ THE FULL QNRX RESEARCH REPORT
Quoin Pharmaceuticals (NASDAQ: QNRX) is a late clinical stage, specialty pharmaceutical company focused on developing treatments for rare and orphan diseases. The company is advancing its lead asset, QRX003, as well as pipeline assets. Ongoing clinical studies have generated positive data thus far, and QNRX plans to expand its clinical activities in 2H 2026. In addition, QRX003 has multiple regulatory designations in place and others under review that provide economic and potentially timeline benefits.
QRX003 is being evaluated for the treatment of NS, pediatric NS, and Peeling Skin Syndrome (PSS). QRX003 is a topical lotion with a broad-spectrum serine protease inhibitor that has demonstrated the ability to significantly downregulate the hyperactivity of the kallikreins in the skin that are responsible for the excessive skin shedding that is associated with NS and other dermatological diseases.
Quoin is currently conducting two pivotal clinical studies for QRX003 in Netherton Syndrome (NS). Quoin expects to report topline data in 2H 2026. Clinical data thus far has demonstrated clear evidence of rapid, prolonged, and almost complete skin healing following twice-daily application of QRX003 to the treatment areas. The company believes QRX003 is on track to potentially become the first approved treatment for NS and believes the worldwide NS commercial opportunity could exceed $1 billion.
Company believes multiple regulatory designations reinforce QRX003’s potential
Once QRX003 and potentially other assets are commercialized, Quoin has identified three core markets - the U.S., E.U, and Japan - and has multiple regulatory designations for QRX003 in place and/or under review in these and other regions. Specifically, the FDA and European Medicines Agency (EMA) have granted QRX003 Orphan Drug Designation (ODD) for the treatment of NS. Following a meeting with Japan’s regulatory authority, the Japanese Ministry of Health, Labour and Welfare (MHLW), Quoin recently submitted an application for Orphan Drug Designation for QRX003 for the treatment of NS for that market (see below) and is optimistic that it will be granted.
QRX003 also received U.S. FDA-granted Fast Track Designation for the treatment of NS on March 11, 2026. Fast Track Designation is designed to expedite the review of drugs that treat serious conditions and fill an unmet medical need, and potentially enable more frequent interactions with the FDA, as well as potential qualification for Accelerated Approval and Priority Review.
Among other benefits, these designations provide economic incentives or credits and potentially can accelerate the timeline for attaining regulatory approval and market exclusivity for a period for QRX003, if approved. The drug candidate has also been granted FDA Rare Pediatric Disease (RPD) Designation for the treatment of NS. With this designation, Quoin potentially could obtain a tradable Priority Review Voucher valued at $150 million to $200 million in non-dilutive cash.
The company believes these designations reinforce the potential of QRX003 as a therapeutic candidate as it advances clinical studies towards a potential New Drug Application (NDA). Moreover, the potential for an expedited regulatory pathway is supported by the significant increase in approvals of products to treat rare and orphan diseases in recent years.
The MHLW confirmed that QRX003 qualifies for both ODD and Fast Track regulatory review in Japan. Japan’s ODD designation would provide benefits such as R&D subsidies, tax credits for qualified clinical testing, reduction of MHLW application fees, priority review and ten years of market exclusivity, if QRX003 is approved.
Separately, Quoin also filed an application for Breakthrough Medicine Designation for QRX003 with the Saudi Food and Drug Authority (SFDA) for the treatment of NS. Such designation would allow for accelerated regulatory review and could enable earlier patient access and reimbursement in Saudi Arabia, where Quoin has formed a distribution partnership with Genpharm for QRX003 (for Saudi Arabia and other MENA countries), potentially as early as 2H 2026, establishing QRX003 as the first approved treatment anywhere for NS.
QNRX has established a worldwide sales network to prepare for commercializing QRX003, other assets
Quoin provided an update from its constructive Type C meeting with the FDA for QRX003 in NS in March 2026. Following the meeting, the FDA indicated that a single Phase 3 study might be sufficient to support regulatory approval. The FDA also indicated it might be open to an alternative study design for Phase 3 that likely would not include a traditional upfront vehicle or placebo control. Quoin plans to initiate its Phase 3 study and complete patient recruitment in 2026. Subsequently, the company targets potentially filing for NDA approval in 2027.
As QNRX moves QRX003 forward in clinical development towards potential regulatory approval and commercialization, its go-to-market plan centers on a proprietary sales infrastructure for core markets the U.S., E.U. and Japan, as noted, and QNRX has established an extensive distribution network for QRX003 and potentially other assets in its pipeline encompassing at least 61 countries through distribution agreements, including:
- Australia
- New Zealand
- The Middle East
- Central and Eastern Europe
- Turkey
- Canada
- China
- Taiwan
- Hong Kong
- Singapore
- Major countries in Latin America
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.